1.	Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLBH589DUS71, NCT01083602
2.	Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 120 Sponsor: Pharmaceutical / Industry Protocol IDs: CLBH589B2201, NCT00425555
3.	Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis) Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLBH589B2211, NCT00449761
4.	Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLBH589B2202, NCT00451035
5.	Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLBH589B2212, NCT00490776
6.	Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLBH589D2308, 2009-015507-52, NCT01023308
7.	A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLBH589E2301, 2009-014846-26, NCT01034163
8.	A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLBH589B2102, NCT00621244
9.	LBH589 Plus Decitabine for Myelodysplastic Syndromes or Acute Myeloid Leukemia Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 60 and over Sponsor: Other Protocol IDs: 08-0172 / 201012979, NCT00691938
10.	Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2008-0805, NCT00967044
11.	LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: SCRI GU 49, NCT00550277
12.	LBH589 in Refractory Myelodysplastic Syndromes (MDS) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: SCRI MDS 07, NCT00594230
13.	Efficacy and Safety Study of Panobinostat in Patients With Metastatic Hormone Refractory Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLBH589C2208, NCT00667862
14.	Phase II Trial of LBH589 in Refractory Colorectal Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CLBH589BUS19T, CRC GOLP CNOV 0823, NCT00690677
15.	Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000601203, P30CA033572, CHNMC-07174, NOVARTIS-CHNMC-07174, 07174, NCT00723203
16.	Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLBH589E2214, 2008-003016-35, NCT00742027
17.	Study of Panobinostat Monotherapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: TRIO 017, NCT00777049
18.	Efficacy and Safety of Panobinostat (LBH5789) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLBH589B2213, 2008-002983-32, NCT00880269
19.	LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 09-071, CLBH589CUS56T, NCT00936611
20.	Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2007-0713, NCT00939159
21.	Study of Panobinostat in Patients With Neuroendocrine Tumors Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 2010-0050 (CO08209), CLBH589BUS38T, NCT00985946
22.	Trial of LBH589 in Metastatic Thyroid Cancer Phase: Phase II Type: Treatment Status: Temporarily closed Age: 18 and over Sponsor: Other Protocol IDs: H-2009-0173, CO 08322, NCT01013597
23.	Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: ESTIM-LBH, 2009-011280-37, NCT01136499
24.	A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589 Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLBH589B2108, NCT00472368
25.	A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLBH589B2110, NCT00503451